Phenytoin (PHT), 5,5-diphenyl-2,4-imidazolidinedione, has been widely used in the management of patients with epilepsy, generalized convulsion and partial seizure. 1,2 PHT has been well established to have non-linear "dose dependent" pharmacokinetic properties and a narrow therapeutic range of 10 -20 µg/ml in serum. 3, 4 Moreover, because PHT is ~90% bound to plasma protein, mainly to albumin 5 , the unbound concentration has been shown to be a better predictor of the therapeutic response than the total concentration. An accurate determination of the unbound-PHT concentration in serum is thus essential for therapeutic drug monitoring.
lytical method. 5-(4-Methylphenyl)-5-phenylhydantoin (MPPH) was used as an internal standard. Unboundand total-PHT and the metabolites levels in the sera from two healthy male volunteers, after the oral administration of PHT, were measured by the established method. An unbound fraction was prepared by ultrafiltration of the serum with the Centrifree ® system.
Experimental

Chemicals and solutions
All chemicals were of analytical-reagent grade, unless otherwise noted. Distilled water, purified with Milli-Q system (Japan Millipore Ltd., Tokyo Japan), was used for all aqueous solutions. PHT, 3HPPH, 4HPPH and MPPH were purchased from Sigma (St. Louis, MO, USA). Br-DMEQ was prepared as described previously 12 , and is now available from Dojindo Laboratories (Kumamoto, Japan). Acetonitrile, which was dehydrated by adding molecular sieves for 2 d, was used for derivatization.
Br-DMEQ (1.3 mM) and dibenzo-18-crown-6 (DB-18-C-6, 5.0 mM) solutions were both prepared in acetonitrile. The Br-DMEQ solutions could be used for more than two days when stored in a refrigerator at 4˚C. PHT, 3HPPH, 4HPPH and MPPH solutions (400 µg/ml each) were prepared in acetonitrile and stored in a refrigerator at 4˚C, which were then further diluted to appropriate concentrations with acetonitrile before undergoing analysis.
HPLC apparatus and conditions
A Shimadzu LC-10AT high-performance liquid chromatograph equipped with a sample injector (10-µl loop) and a Shimadzu RF-10AXL fluorescence detector fitted with a 12-µl flow-cell were used. It was operated at an excitation wavelength of 365 nm and an emission wavelength of 448 nm. The separations were performed on a YMC-Pack ODS-A reversed-phase column (250×4.6 mm i.d., 5 µm; YMC Co., Ltd, Kyoto, Japan), which was preceded by a YMC-Pack ODS-A guard column (10×4.0 mm i.d.; particle size, 5 µm) by isocratic elution with a mixture of acetonitrile-50 mM phosphate buffer (pH 7.0) (4:6, v/v) at a flow rate of 1.0 ml/min. The column temperature was ambient (20 -25˚C). The uncorrected fluorescence excitation and emission spectra of the eluates were measured with a Hitachi 650-60 fluorescence spectrophotometer (Tokyo, Japan) fitted with a 20-µl flow-cell; the spectral bandwidths were 5 nm in both the excitation and emission monochromators.
Serum samples
Healthy male volunteers were given a 200 mg single oral dose of PHT. After administering the drug, blood samples were withdrawn at 2, 3, 4, 6, 8, 10 and 12 h, and each sample was allowed to stand for 30 min at room temperature (20 -25˚C), and was then centrifuged at 1000g for 10 min. For the unbound fraction preparation, a 150-µl aliquot of the serum was immediately ultrafiltered with a Centrifree micropartition device from Amicon (Beverly, MA, USA). Each serum and ultrafiltrate (for unbound fraction) sample was frozen on dry-ice immediately after collection, and stored at -40˚C before use.
Extraction and derivatization procedure
A 50-µl aliquot of the serum sample was added with 5 µl of the MPPH (internal standard) solution, and the mixture was allowed to stand at room temperature for ca. 3 min. To the resulting solution, 250 µl of saturated potassium hydrogen carbonate solution, and 1.0 ml of ethyl acetate were added. The mixture was vortexed for ca. 2 min and centrifuged at 1000g for 5 min. The organic layer (ca. 800 µl) was placed in a screw-capped test tube (4 ml) and evaporated to dryness under a nitrogen stream. Then, ca. 15 mg of a mixture of potassium hydrogen carbonate and anhydrous sodium sulfate (1:2, w/w) and 100 µl each of the Br-DMEQ and DB-18-C-6 solutions were added to the tube. The tube was tightly closed and maintained at 80˚C for 70 min. After cooling, 10 µl of the resulting mixture was injected into the chromatograph. To determine the total levels of PHT and the metabolites in serum, the serum was prepared by 10-fold dilution with water as a serum sample, and then treated according to the derivatization procedure.
For the calibration curve, 5 µl of the MPPH solution containing 1.0 ng to 1.0 µg each of PHT, 3HPPH and 4HPPH in place of 5 µl of the MPPH solution was carried out by the procedure using 50 µl of drug-free serum. The peak-height ratios of the individual compounds and MPPH were plotted against the concentrations of the spiked compounds.
Results and Discussion
HPLC conditions and derivatization conditions
A complete base-line separation of the DMEQ derivatives of PHT, 3HPPH, 4HPPH and MPPH was achieved on a YMC-Pack ODS-A reversed-phase column with acetonitrile-50 mM phosphate buffer (pH 7.0) (4:6, v/v) as an eluent. Figure 1 shows a typical chromatogram obtained with a standard mixture of PHT, 3HPPH, 4HPPH and MPPH. The capacity factors for 3HPPH, 4HPPH, PHT and MPPH were 9.47, 12.4, 13.2 and 18.2, respectively.
The derivatization reaction of PHT, 3HPPH, 4HPPH and MPPH with Br-DMEQ apparently occurred even at 37˚C, while higher temperatures allowed the fluorescence to develop more rapidly. An example of PHT is shown in Fig. 2 . At 80˚C, the peak heights for all the compounds were almost maximal after heating for 60 min. Heating for 70 min at 80˚C was thus employed for this procedure. The DMEQ derivatives in the final mixture were stable and gave a constant peak height for 372 ANALYTICAL SCIENCES APRIL 1999, VOL. 15
at least 6 h in daylight at room temperature. Br-DMEQ gave the most intense peaks at concentrations greater than 1.0 mM in the solution. However, peaks 5 and 6 ( Fig. 1) , due to the reagent blank, increased in height and width upon increasing the reagent concentration, which interfered with the determination of 3HPPH. Therefore, 1.3 mM Br-DMEQ was used in this procedure.
The maximum and constant peak heights were attained at DB-18-C-6 concentrations in a solution greater than 3.0 mM, and 5.0 mM was selected as the standard solution for this procedure.
Potassium hydrogen carbonate gave the most intense peaks at an amount of 4.0 -7.0 mg for all compounds; then, 5.0 mg of the hydrogen carbonate was selected as the standard for this procedure. In order to obtain sufficient reproducibility of the amount of hydrogen carbonate taken, a mixture (15 mg) of potassium hydrogen carbonate and anhydrous sodium sulfate (1:2, w/w) was used. The sulfate did not interfere with the derivatization of these compounds with Br-DMEQ. When potassium carbonate was used, peaks 5 -7 became larger and broader than those obtained with potassium hydrogen carbonate.
The chemical structure of the Br-DMEQ derivatives of PHT and the metabolites is not known. Iwamoto et al. confirmed that some uracil compounds, such as 1-(tetrahydro-2-furanyl)-5-fluorouracil, which has an active imino hydrogen group, react with 4-bromomethyl-7-methoxycoumarin (Br-MMC) in the presence of 18-crown-6 and potassium carbonate to form the alkylated derivative. 16 It is considered that Br-DMEQ is also an alkylating agent as well as Br-MMC in respect of reactivity.
Determination of the unbound-and total-PHT, and its metabolites in the serum
To obtain the unbound drug fractions in the serum, both equilibrium dialysis and ultrafiltration are commonly utilized; however, equilibrium dialysis is timeconsuming (17 -19 h). 17 As a result, ultrafiltation with a Centrifree micropartition device was chosen for convenient preparation of the unbound fraction. To determine the total-PHT level, the serum was diluted 10-fold with water, and directly treated without ultrafiltration.
PHT, 3HPPH, 4HPPH and MPPH were effectively extracted from serum samples (diluted serum and ultrafiltrate) with ethyl acetate after adding a saturated potassium hydrogen carbonate solution. The individual recoveries of PHT, 3HPPH, 4HPPH and MPPH were almost the same in the concentration range of 50 ng -5.0 µg/ml ( Table 1) . As a result, excellent recovery was obtained for all compounds of each group, except for 3HPPH. Figure 3 shows typical chromatograms obtained with the drug-free serum (A) and with the same serum (B) spiked with PHT, 3HPPH, 4HPPH and MPPH (IS). The pattern of the chromatograms for the spiked serum was virtually identical with Fig. 1 . No interfering peaks were observed around the retention times of these compounds when both the drug-free serum and its ultrafiltrate were treated as in the procedure (Fig. 3A) . Peaks 1 -4 in Fig. 3B were identified as the DMEQ derivatives of 3HPPH, 4HPPH, PHT and MPPH, respectively, based on their retention times and the fluorescence excitation and emission spectra of the eluates in com- parison with the standard compounds, and also by cochromatography of the standards and the serum sample using aqueous 35 -45% acetonitrile as the mobile phases.
The relationships between the ratios of the peak heights of PHT, 3HPPH and 4HPPH to that of MPPH and the amounts of PHT, 3HPPH and 4HPPH were linear over the range of 1.0 ng -1.0 µg in 50 µl of serum sample, and the slope of the curve did not change depending on the serum sample that was used. The linear-regression equations [the linear correlation coefficients (n=7) in parentheses] of the curves for PHT, 3HPPH and 4HPPH were y =1.2085x+0.0036 (0.995), y=0.1621x+0.0081 (0.987) and y=0.3190x-0.0013 (1.000), respectively; here, y and x are the peak-height ratio and the concentration (ng ml -1 in the serum) of the individual compounds, respectively. These results show that the present internal standard method thus allows us to determine the levels of PHT and the metabolites in serum samples over a wide range of concentrations.
The within-and between-day precisions were examined by performing eight separate analyses using sera spiked with PHT, 3HPPH and 4HPPH at concentrations of 500 ng ml -1 and 50 ng ml -1 . The between-day precision was obtained by performing analyses during eight days with the sera kept at -40˚C. The results are listed in Table 2 . The relative standard deviations (RSD) did not exceed 4.5% for all of the cases tested.
The detection limits (signal-to-noise ratio=3) for PHT, 3HPPH and 4HPPH were 0.6, 3.0 and 0.8 ng (2.4, 11 and 3.1 pmol) per ml serum or ultrafiltrate (6, 28 and 8 fmol on column), respectively. The sensitivity is 1000 -2000 times higher than those of the UV-HPLC methods. [9] [10] [11] In order to evaluate the proposed method for clinical use, it was applied to monitoring the unbound and total drug concentrations in serum samples obtained after a single oral dose of PHT (200 mg). Figure 4 shows the time-concentration curves obtained by the serum samples. 3HPPH and 4HPPH could not be detected in the observation period. The reason for this may have been that these metabolites are further converted into those glucuronides. 18 The unbound-and total-PHT concentration curves were similarly changed, and the concentrations reached a maximum value at 4 h after oral 374 ANALYTICAL SCIENCES APRIL 1999, VOL. 15 This study described the first HPLC method using fluorescence detection for the simultaneous determination of PHT and its metabolites (3HPPH and 4HPPH). The sensitivity of this method was adequate for measuring the unbound-PHT in 50 µl of the ultrafitrate (ca. 150 µl of serum). This method is simple and may therefore be useful as a routine analysis for the therapeutic drug monitoring of PHT. Furthermore, this method may also be useful for conducting pharmacokinetic studies of PHT.
